We really don't disagree, but I've been saying for
Post# of 15624
Perhaps their initial failure to communicate clearly resulted in an unwarranted rise to over $3, but they never really explained when if all goes right they'll be on the market with the cream or sublingual tablet. If you've ever invested in Biotech's you know it's unlikely that everything will go right, their will typically be delays, but I believe their unclear language had most of us convinced we'd have a cosmetic product on the market by July or earlier.
I would hope that the quarterly gives us a realistic view of where we're headed.
Gary